For research use only. Not for therapeutic Use.
Kallikrein 5-IN-2 (compound 21) is a selective Kallikrein KLK5 inhibitor (pIC50=7.1). KLK5 inhibition may normalise epidermal shedding and reduce the associated inflammation and itching[1].
Catalog Number | I041749 |
CAS Number | 2361160-57-6 |
Synonyms | 4-[(5-phenyl-1H-imidazol-2-yl)methylamino]-2-(pyridin-3-ylmethoxy)benzenecarboximidamide |
Molecular Formula | C23H22N6O |
Purity | ≥95% |
InChI | InChI=1S/C23H22N6O/c24-23(25)19-9-8-18(11-21(19)30-15-16-5-4-10-26-12-16)27-14-22-28-13-20(29-22)17-6-2-1-3-7-17/h1-13,27H,14-15H2,(H3,24,25)(H,28,29) |
InChIKey | ZDLCAMFQMDNCSU-UHFFFAOYSA-N |
SMILES | C1=CC=C(C=C1)C2=CN=C(N2)CNC3=CC(=C(C=C3)C(=N)N)OCC4=CN=CC=C4 |
Reference | [1]. Walker AL, et al. Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1454-1458. |